<DOC>
	<DOCNO>NCT02481323</DOCNO>
	<brief_summary>Phase II pilot randomise , factorial , short term dose escalation , open label , blind intermediary endpoint trial , two hospital centre UK , tolerability safety cilostazol , isosorbide mononitrate , neither patient small vessel disease manifest symptomatic small subcortical stroke .</brief_summary>
	<brief_title>Lacunar Intervention Trial 1 ( LACI-1 )</brief_title>
	<detailed_description>A quarter ischaemic stroke lacunar ( small vessel ) type , 35000 per annum United Kingdom , due intrinsic , non-atheromatous , non-cardioembolic perforate cerebral arteriolar disease . 'Small vessel disease ' also affect brain diffusely , cause 40 % dementia , alone mixed Alzheimer 's disease , 350,000+ patient estimate currently United Kingdom . There proven treatment : conventional antiplatelet drug may ineffective even hazardous , antihypertensive treatment statin disappoint . The disease mechanism poorly understood endothelial dysfunction , blood-brain barrier failure vessel stiffness appear contribute pathogenesis . Promising data available licensed drug relevant mode action , cilostazol ( &gt; 6000 stroke patient Asia Pacific region ) isosorbide mononitrate ( ISMN , widely use cardiac disease ) support test small vessel disease . This trial phase 2 , randomise , dose-escalation , factorial trial test short-term administration cilostazol , Isosorbide Mononitrate , , neither , provide data patient tolerability dose ( include headache , dizziness ) , safety ( include blood pressure , platelet function ) , provide mechanistic evidence efficacy ( cerebrovascular reactivity , arterial compliance ) , inform design large phase 2-3 trial . The trial recruit 60 patient small vessel disease , two expert stroke centre ( Edinburgh Nottingham ) suitable patient , expert stroke centre , establish trial infrastructure neuroimaging platelet test expertise . The trial also advance method stratify patient small vessel disease burden routine practise data intermediary mechanistic outcome assist plan future trial test novel agent either stroke dementia .</detailed_description>
	<mesh_term>Cognition Disorders</mesh_term>
	<mesh_term>Cerebral Small Vessel Diseases</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<mesh_term>Isosorbide-5-mononitrate</mesh_term>
	<mesh_term>Isosorbide Dinitrate</mesh_term>
	<mesh_term>Isosorbide</mesh_term>
	<criteria>Mild symptomatic ischaemic stroke past four year compatible clinical lacunar stroke syndrome , brain magnetic resonance imaging compute tomography scan compatible symptomatic small subcortical ( lacunar ) infarct , recent relevant infarct visible , exclude cause symptom Age &gt; 35 year Independent activity daily live ( modified Rankin ≤2 ) Able give consent Other significant active neurological illness present since suffer stroke ( eg seizure , multiple sclerosis , brain tumour ) Age &lt; 35 Montreal Cognitive Assessment score &lt; 26 Requiring assistance activity daily live ( Modified Rankin ≥3 ) Active cardiac disease ( atrial fibrillation , myocardial infarction past 6 month , active angina , symptomatic cardiac failure ) Carotid stenosis &gt; 50 % symptomatic artery territory require carotid endarterectomy ( prior apparently successful carotid endarterectomy exclusion criterion ) Definite indication , definite contraindication either trial drug Unable swallow Bleeding tendency ( platelet &lt; 100 , take anticoagulant medication ) Unlikely comply trial medication Planned surgery trial period History intracranial haemorrhage ( subdural haematoma , subarachnoid haemorrhage , intracerebral haemorrhage , asymptomatic haemorrhagic transformation infarction ) Other life threaten illness History drug overdose attempt suicide significant active mental illness Pregnancy If recruit Edinburgh participate cerebrovascular reactivity arm trial : active respiratory illness ( moderate severe asthma chronic obstructive airway disease ) , unable tolerate magnetic resonance image unable lie flat</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>cerebral small vessel disease</keyword>
	<keyword>cerebrovascular reactivity</keyword>
	<keyword>cilostazol</keyword>
	<keyword>isosorbide mononitrate</keyword>
</DOC>